Amgen cancer drug combo cuts death risk 58% in late-stage trial

Amgen (AMGN) reported that pairing its drug Imdelltra with AstraZeneca's Imfinzi cut the risk of death by 58% in patients with an aggressive, fast-spreading form of lung cancer. The gain came with more side effects. Both politicians tracked here hold the stock long.

Sources

Amgen's Imdelltra Plus AstraZeneca's Imfinzi Cuts Death Risk 58% in Aggressive Small Cell Lung Cancer, With Higher Side Effects
The whole story · updated
R
Reuters
·
Amgen drug combined with immunotherapy extends survival in lung cancer trial
CN
CNBC
·
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in